Tags

Type your tag names separated by a space and hit enter

Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017.
Subst Abuse. 2020; 14:1178221820930006.SA

Abstract

Objective

To analyze the rates of misuse - that is, use in any way not directed by a doctor - of products containing oral tramadol, a Schedule IV opioid, from the National Survey of Drug Use and Health (NSDUH), as compared to comparator Schedule II opioids (morphine, oxycodone, and hydrocodone) and alprazolam, a commonly prescribed Schedule IV controlled substance in the U.S.

Methods

The NSDUH is a congressionally mandated household survey that collects information on tobacco, alcohol, and drug use, mental health and other health-related issues in the US. A cross-sectional surveillance study design was used to examine lifetime and past year misuse of oral tramadol and comparators of interest among NSHUH respondents aged 12 years or older. Based on when particular data were available, the past-year misuse analysis includes NSDUH data from 2015 to 2017, and the lifetime misuse analysis includes NSDUH data from 2002 to 2014.

Results

In 2015 to 2017, past-year misuse of oral tramadol was approximately 4% of the total number of prescriptions, versus 7% to 8% for all of the comparators when adjusted for drug availability. In 2002 to 2014, lifetime misuse of oral tramadol remained at 1.5% or less over the 13-year period, and was lower than reported for hydrocodone (6%) and oxycodone (4%), respectively. Comparison of oral tramadol and alprazolam showed misuse of tramadol was also much lower than alprazolam. Too few reports of tramadol misuse by injection (n = 7) were reported, versus 570, 1096, and 32 reports of injection of morphine, oxycodone, and hydrocodone, respectively, during the 16-year analysis period to allow for any population-based estimation. Only morphine has an intravenous formulation available and tramadol was not available as an intravenous formulation in the U.S. during that time period.

Conclusions

This analysis shows a low prevalence of oral tramadol misuse, relative to other commonly prescribed opioids, in a nationally representative sample of noninstitutionalized US residents. Estimates of reported oral tramadol misuse have remained relatively stable over time and are substantially lower than those reported for comparators when adjusted for prescription volume. Reports of oral tramadol misuse are also much less than alprazolam, another Schedule IV drug.

Authors+Show Affiliations

Avenue Therapeutics, New York, NY, USA.Goldmann Consulting LLC, Bradenton, FL, USA.Avenue Therapeutics, New York, NY, USA.Avenue Therapeutics, New York, NY, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32547049

Citation

Reines, Scott A., et al. "Misuse of Tramadol in the United States: an Analysis of the National Survey of Drug Use and Health 2002-2017." Substance Abuse : Research and Treatment, vol. 14, 2020, p. 1178221820930006.
Reines SA, Goldmann B, Harnett M, et al. Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017. Subst Abuse. 2020;14:1178221820930006.
Reines, S. A., Goldmann, B., Harnett, M., & Lu, L. (2020). Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017. Substance Abuse : Research and Treatment, 14, 1178221820930006. https://doi.org/10.1177/1178221820930006
Reines SA, et al. Misuse of Tramadol in the United States: an Analysis of the National Survey of Drug Use and Health 2002-2017. Subst Abuse. 2020;14:1178221820930006. PubMed PMID: 32547049.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Misuse of Tramadol in the United States: An Analysis of the National Survey of Drug Use and Health 2002-2017. AU - Reines,Scott A, AU - Goldmann,Bonnie, AU - Harnett,Mark, AU - Lu,Lucy, Y1 - 2020/06/03/ PY - 2020/04/06/received PY - 2020/05/01/accepted PY - 2020/6/18/entrez PY - 2020/6/18/pubmed PY - 2020/6/18/medline KW - NSDUH KW - alprazolam KW - misuse KW - opiates KW - tramadol SP - 1178221820930006 EP - 1178221820930006 JF - Substance abuse : research and treatment JO - Subst Abuse VL - 14 N2 - Objective: To analyze the rates of misuse - that is, use in any way not directed by a doctor - of products containing oral tramadol, a Schedule IV opioid, from the National Survey of Drug Use and Health (NSDUH), as compared to comparator Schedule II opioids (morphine, oxycodone, and hydrocodone) and alprazolam, a commonly prescribed Schedule IV controlled substance in the U.S. Methods: The NSDUH is a congressionally mandated household survey that collects information on tobacco, alcohol, and drug use, mental health and other health-related issues in the US. A cross-sectional surveillance study design was used to examine lifetime and past year misuse of oral tramadol and comparators of interest among NSHUH respondents aged 12 years or older. Based on when particular data were available, the past-year misuse analysis includes NSDUH data from 2015 to 2017, and the lifetime misuse analysis includes NSDUH data from 2002 to 2014. Results: In 2015 to 2017, past-year misuse of oral tramadol was approximately 4% of the total number of prescriptions, versus 7% to 8% for all of the comparators when adjusted for drug availability. In 2002 to 2014, lifetime misuse of oral tramadol remained at 1.5% or less over the 13-year period, and was lower than reported for hydrocodone (6%) and oxycodone (4%), respectively. Comparison of oral tramadol and alprazolam showed misuse of tramadol was also much lower than alprazolam. Too few reports of tramadol misuse by injection (n = 7) were reported, versus 570, 1096, and 32 reports of injection of morphine, oxycodone, and hydrocodone, respectively, during the 16-year analysis period to allow for any population-based estimation. Only morphine has an intravenous formulation available and tramadol was not available as an intravenous formulation in the U.S. during that time period. Conclusions: This analysis shows a low prevalence of oral tramadol misuse, relative to other commonly prescribed opioids, in a nationally representative sample of noninstitutionalized US residents. Estimates of reported oral tramadol misuse have remained relatively stable over time and are substantially lower than those reported for comparators when adjusted for prescription volume. Reports of oral tramadol misuse are also much less than alprazolam, another Schedule IV drug. SN - 1178-2218 UR - https://www.unboundmedicine.com/medline/citation/32547049/Misuse_of_Tramadol_in_the_United_States:_An_Analysis_of_the_National_Survey_of_Drug_Use_and_Health_2002-2017 L2 - https://journals.sagepub.com/doi/10.1177/1178221820930006?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=www.ncbi.nlm.nih.gov DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.